{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:24:44Z","timestamp":1793057084754,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:03:41Z","timestamp":1736039021000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-9337","authenticated-orcid":false,"given":"Edith T.","family":"Zemanick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F.","family":"McKone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-1486","authenticated-orcid":false,"given":"Isabelle","family":"Fajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Arteaga-Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Van Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Prieto-Centurion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Sosnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-6018","authenticated-orcid":false,"given":"David","family":"Waltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2024.12.006_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.jcf.2024.12.006_bib0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir Care"},{"issue":"5","key":"10.1016\/j.jcf.2024.12.006_bib0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.12.006_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2022.07.015","article-title":"Disease severity of people with cystic fibrosis carrying residual function mutations: data from the ECFS patient registry","volume":"22","author":"Zahav","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"9370","key":"10.1016\/j.jcf.2024.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(03)13368-5","article-title":"Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study","volume":"361","author":"McKone","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jcf.2024.12.006_bib0006","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.12.006_bib0007","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcf.2024.12.006_bib0008","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jcf.2022.01.004","article-title":"Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme","volume":"21","author":"Cirilli","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"9678","key":"10.1016\/j.jcf.2024.12.006_bib0009","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2024.12.006_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1513\/pats.200703-043BR","article-title":"Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials","volume":"4","author":"Rowe","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.12.006_bib0011","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.jcf.2024.12.006_bib0012","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201205-0922OC","article-title":"\u03b2-adrenergic sweat secretion as a diagnostic test for cystic fibrosis","volume":"186","author":"Quinton","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.12.006_bib0013","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00439-005-0059-z","article-title":"The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis","volume":"118","author":"Bishop","year":"2005","journal-title":"Hum. Genet."},{"issue":"3","key":"10.1016\/j.jcf.2024.12.006_bib0014","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcf.2022.02.001","article-title":"How the sweat gland reveals levels of CFTR activity","volume":"21","author":"Wine","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"17","key":"10.1016\/j.jcf.2024.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"46","key":"10.1016\/j.jcf.2024.12.006_bib0016","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.jcf.2024.12.006_bib0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.12.006_bib0018","first-page":"62","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.jcf.2024.12.006_bib0019","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.12.006_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.jcf.2024.12.006_bib0021","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcf.2024.12.006_bib0022","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.12.006_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.12.006_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.jcf.2024.12.006_bib0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.12.006_bib0026","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","article-title":"Year-to-year changes in lung function in individuals with cystic fibrosis","volume":"9","author":"Liou","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.12.006_bib0027","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ppul.20054","article-title":"Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis","volume":"38","author":"Davis","year":"2004","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2024.12.006_bib0028","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jcf.2024.12.006_bib0029","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1378\/chest.14-1997","article-title":"The evolution of cystic fibrosis care","volume":"148","author":"Pittman","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jcf.2024.12.006_bib0030","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/ijms23031437","article-title":"Assays of CFTR function in vitro, ex vivo and In Vivo","volume":"23","author":"Ramalho","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jcf.2024.12.006_bib0031","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"10408","key":"10.1016\/j.jcf.2024.12.006_bib0032","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.12.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with N1303K or other rare <em>CFTR<\/em>variants: a viewpoint","author":"Burgel","year":"2024","journal-title":"Eur Respirat J"},{"key":"10.1016\/j.jcf.2024.12.006_bib0034","doi-asserted-by":"crossref","unstructured":"Solomon, G.M., et al., Elexacaftor-tezacaftor-ivacaftor improves clinical outcomes in individuals with CF encoding N1303K CFTR. 2024. Preprint: p. 1\u201327.","DOI":"10.2139\/ssrn.4745080"},{"key":"10.1016\/j.jcf.2024.12.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","author":"Zemanick","year":"2024","journal-title":"J Cystic Fibrosis"},{"issue":"6","key":"10.1016\/j.jcf.2024.12.006_bib0036","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932401854X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932401854X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:37:01Z","timestamp":1777333021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932401854X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S156919932401854X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.12.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}